NR3C2 and chronic kidney disease: Despite the control of blood pressure by the use of ACE inhibitors or AT1 receptor blockers and significant progress in the treatment of CKD due to recent approvals of the SGLT2 inhibitor dapagliflozin (ForxigaTM) and the non-steroidal MR antagonist finerenone (KerendiaTM), progressive decline in kidney function remains an indication with a significant medical need [15,16].